Cardlytics, Inc. (NASDAQ:CDLX – Get Free Report) has earned an average rating of “Hold” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $6.42.
A number of brokerages recently commented on CDLX. Lake Street Capital dropped their target price on Cardlytics from $5.00 to $3.00 and set a “hold” rating on the stock in a research report on Thursday, March 13th. Evercore ISI decreased their price objective on shares of Cardlytics from $4.00 to $3.00 and set an “in-line” rating for the company in a research note on Thursday, March 13th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Cardlytics in a research note on Thursday, March 13th.
View Our Latest Report on CDLX
Insider Buying and Selling at Cardlytics
Institutional Trading of Cardlytics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CDLX. Mirabella Financial Services LLP acquired a new stake in shares of Cardlytics during the 4th quarter worth about $4,285,000. D. E. Shaw & Co. Inc. boosted its position in Cardlytics by 97.4% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,131,505 shares of the company’s stock worth $4,198,000 after acquiring an additional 558,235 shares during the last quarter. Geode Capital Management LLC grew its stake in Cardlytics by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 1,060,739 shares of the company’s stock worth $3,936,000 after acquiring an additional 7,561 shares during the period. RBF Capital LLC raised its holdings in Cardlytics by 64.7% in the 4th quarter. RBF Capital LLC now owns 803,763 shares of the company’s stock valued at $2,982,000 after acquiring an additional 315,635 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Cardlytics by 3.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 402,552 shares of the company’s stock valued at $1,493,000 after acquiring an additional 12,209 shares during the last quarter. Hedge funds and other institutional investors own 68.10% of the company’s stock.
Cardlytics Price Performance
NASDAQ CDLX opened at $1.50 on Tuesday. The firm’s fifty day simple moving average is $2.22 and its two-hundred day simple moving average is $3.17. The firm has a market capitalization of $78.13 million, a P/E ratio of -0.25 and a beta of 1.39. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. Cardlytics has a 12-month low of $1.22 and a 12-month high of $15.89.
Cardlytics Company Profile
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Read More
- Five stocks we like better than Cardlytics
- What Are Trending Stocks? Trending Stocks Explained
- Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally
- Dividend Payout Ratio Calculator
- Mitigating Tariffs: 3 Stocks to Gain From a Weaker U.S. Dollar
- Ride Out The Recession With These Dividend Kings
- Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.